Drugs /

anti-her2 antibody

Back to Drugs List

Overview

NCI Definition [1]:
Any monoclonal antibody that is directed against human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).

Clinical Trials

View Clinical Trials for anti-her2 antibody

Anti-her2 antibody has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating anti-her2 antibody, 1 is phase 1/phase 2 (1 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for anti-her2 antibody clinical trials.

Breast carcinoma and gastric carcinoma are the most common diseases being investigated in anti-her2 antibody clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Anti-Her2 Antibody
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating anti-her2 antibody and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-erbb2 monoclonal antibody, anti-her2 monoclonal antibody, anti-her-2 monoclonal antibody
Drug Target(s) [2]:
ERBB2
NCIT ID [1]:
C155711

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.